Amol K. Narang, MD, discusses the improvement in systemic therapy for treatment of pancreatic cancer in recent years. He says that the combination of various chemotherapies are showing potential in a number of trials.
Amol K. Narang, MD, assistant professor of radiation oncology and molecular radiation sciences, John Hopkins Sidney Kimmel Comprehensive Cancer Center, discusses the improvement in systemic therapy for the treatment of pancreatic cancer in recent years. He says that the combination of various chemotherapies are showing potential in a number of trials.
In 2 landmark studies, the combination of FOLFIRINOX [folinic acid, fluorouracil (5-FU), irinotecan, and oxaliplatin] with gemcitabine and paclitaxel has shown significant improvement over the standard of care, gemcitabine alone.
The Impact of the Gut Microbiome in Young Patients With Colorectal Cancer
February 15th 2021In season 2, episode 2 of Targeted Talks, Cathy Eng, MD, speaks with Benjamin Weinberg, MD, about the gut microbiome, and how the presence of certain microbiota impact the onset and intensity of disease as well as the potential response to certain treatments.
Listen